CEO: Martine A. Rothblatt, Chairman & CEO Headquarters: Silver Spring, MD Employees: 285
Analysis:
United Therapeutics' lead product, Remodulin, treats high blood pressure in the pulmonary artery. Patients with chronic and life threatening illnesses, such as cancer, cardiovascular and infectious diseases, also rely on medicines developed by this biotechnology company. UTHR is developing an oncology drug for ovarian cancer.
Financials
Revenue (millions, 2006)
$159.6
Revenue growth (3-year annualized)
45.51%
Annual net income (millions, 2006)
$74.0
Earnings per share growth (3-year annualized)
148.41%
Return for investors (3-year annualized)
33.31%
Source: Zacks
From the July/August 2007 Issue of FSB magazine
Notes: An earlier version of this table had incorrect revenue and net income numbers for some of the companies. CNNMoney.com regrets the error.
In our seventh annual list, we once again asked financial research firm Zacks to rank public companies with revenues of less than $200 million and a stock price of more than $1, based on their percentage growth in earnings, revenue, and stock performance over the past three years. (Banks, real estate firms and adult entertainment companies were excluded.) If you have further questions about the FSB 100, please e-mail lists@cnnmoney.com.
Lessons from the fastest
What does it take to catapult your company onto the FSB 100? Innovation and persistence, of course. But this year it also helped if you worked in industrial manufacturing. Although conventional wisdom holds that U.S. factories are trapped in a death spiral thanks to cheap overseas labor, a quarter of our fast-growth all-stars are finding creative ways to thrive in the bent-metal sector, up from 3 percent in 2003. Another 21 companies are building profitable niches in health care, selling everything from new drugs to remote patient monitors. Tech plays round out the top three categories, with 18 companies providing a smorgasbord of software and semiconductor products. (more)
How we pick the 25 richest executives
Equilar, an executive-compensation research firm in San Mateo, Calif., reviewed proxy statements for firms on the FSB 100 list. When the shares owned outright and vested options are factored in, these 25 executives have the most bling.
